Patients with liver cirrhosis have an impaired immune response. Often, liver cirrhosis patients experience complications from portal hypertension, such as gastroesophageal varices. These varices can bleed, increasing the risk of infection and death in a short period of time, despite proper endoscopic management. Patients who develop bacterial infections during hospitalisation for gastroesophageal haemorrhage are at increased risk of dying. Twelve trials (1241 patients) assessing several antibiotic prophylaxis regimens versus no intervention or placebo were analysed, showing that antibiotic prophylaxis successfully reduced the incidence of bacterial infections. Antibiotic prophylaxis was also associated with a reduction in mortality, mortality from bacterial infections, rebleeding rate, and days of hospitalisation. The prophylactic treatment was not associated with important adverse effects. Five trials (650 patients) assessed one antibiotic regimen compared with another. All antibiotic regimens provided similar benefits and none seemed superior. Thus, to this point there is no evidence to recommend one specific antibiotic regimen over the other. All trials analysed were subject to bias; thus, results should be interpreted carefully.
Antibiotic prophylaxis for prevention of bacterial infections and death in cirrhotic patients with upper gastrointestinal bleeding
Have your say!
'Your views on The Cochrane Library: survey'
Published Online:
September 8, 2010
More like this
- Evidence to establish the beneficial and harmful effects of antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients is lacking
- No sufficient evidence to prove with certainty that human recombinant activated factor VII reduces or not the risk of death in patients with liver disease suffering from upper gastrointestinal bleeding
- There is no evidence to establish the beneficial or harmful effects of vitamin K for upper gastrointestinal bleeding in patients with liver diseases
- There is no evidence from randomised clinical trials to establish the beneficial or harmful effects of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with liver disease plus acquired coagulation disorders
- Existing trials, of poor quality, indicate that antibiotic prophylaxis reduces spontaneous bacterial peritonitis among cirrhotic patients with ascites and no gastrointestinal bleeding
